Repligen entered into an Agreement and Plan of Merger to acquire BioLife Solutions in a cash-and-stock transaction. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each BioLife share through a two-step merger. Closing is subject to customary conditions including BioLife stockholder approval, HSR clearance, SEC effectiveness of a Form S-4, and Nasdaq listing, with completion targeted for Q4 2026. The agreement includes standard covenants and a $59 million termination fee payable by BioLife in certain circumstances.
Agreement details:
- Agreement type: Agreement and Plan of Merger
- Counterparty: BioLife Solutions
- Signed / Effective: Jul 21 2026 / N/A
- Reason: Expand bioprocessing footprint and accelerate growth in cell therapy tools
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.